Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May;41(5):1494-1498.
doi: 10.12669/pjms.41.5.11002.

Multicenter, Retrospective, observational study to evaluate the real-world use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in the Pakistani population with Type-2 diabetes (T2D)

Umar Yousaf Raja  1 , Muhammad Umar Wahab  2 , Fawad Ahmed Randhawa  3 , Arshad Hussain  4 , Abbas Raza  5 , Saeed Ahmed Mahar  6 , Osama Ishtiaq  7 , Tejhmal Rehman  8 , Faisal Masood Qureshi  9 , Ibrar Ahmed  10
Affiliations

Multicenter, Retrospective, observational study to evaluate the real-world use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in the Pakistani population with Type-2 diabetes (T2D)

Umar Yousaf Raja et al. Pak J Med Sci. 2025 May.

Abstract

Objective: To evaluate the real-world use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in the Pakistani population with type II diabetes (T2D).

Methods: This multicenter, retrospective study collected real-world data from various public & private hospitals, and primary care clinics in Pakistan. The total duration of clinical data collection was six months (April and September 2022) from 183 diabetic patients across different centers in Pakistan. Patients who had received IDegLira in combination with basal/premixed insulin, OHAs, or both regimes (basal/premixed insulin and OHAs) for the treatment of Type-II diabetes (T2D) in the Pakistani population were analyzed.

Results: After receiving IDegLira therapy for six months, mean HbA1c was reduced by -1.1%, mean body weight reduced by 1.2 kg, fasting blood glucose levels (mg/dl): 164.7 (±36.2) to 134.4 (±32.9)] and random blood sugar (mg/dl): 240.1 (±71.4) to 207.6 (±77.8)]. The mean IDegLira dose steps were 19.9 (±6.7) at initiation and 23.5 (±7.9) at follow-up. Overall, adverse events reported were generally related to gastrointestinal, and few were related to headache, fatigue, and hypoglycemia events.

Conclusion: The values of HbA1c and body weight decreased for the patients after using iDeglira for six months. Therefore, the medicine had a positive impact on the outcome of the study.

Keywords: Diabetes mellitus Type-II; HbA1C; IDeglira; Premix insulin.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None.

References

    1. IDF. Diabetes Atlas 2021 |IDF Diabetes Atlas. https://diabetesatlas.org/atlas/tenth-edition/
    1. Liu Y, Li X, Zheng Y, Wang X, Wang X. IDegLira for type 2 diabetes:a systematic review and meta-analysis. Endocrine. 2024;83(3):648–658. doi:10.1007/s12020-023-03543-z. - PubMed
    1. Szépkúti S, Bandur S, Kovács G, Ferenci T, Svébis MM, Turbucz P, et al. Real-world effectiveness of IDegLira compared with intensified conventional insulin therapy in adults with type 2 diabetes:a retrospective cohort study. BMC Endocr Disord. 2022;22(1):229. doi:10.1186/s12902-022-01139-8. - PMC - PubMed
    1. Abusnana S, Al Awadi F, Aly H, Bashier A, Kumar Dhanwal D, Halasa T, et al. Switching to a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) is associated with improved glycaemic control in a real-world population with type 2 diabetes mellitus in the United Arab Emirates:Results from the multicentre, prospective INTENSIFY study. Diabetes Res Clin Pract. 2023;196:110183. doi:10.1016/j.diabres.2022.110183. - PubMed
    1. Malighetti ME, Molteni L, Orsi E, Serra R, Gaglio A, Mazzoleni F, et al. IDegLira improves time in range in a cohort of patients with type 2 diabetes:TiREX study. Acta Diabetol. 2025;62(3):367–374. doi:10.1007/s00592-024-02361-7. - PMC - PubMed

LinkOut - more resources